The global contract development and manufacturing organization (CDMO), Samsung Biologics, announced this week that it has entered into a collaboration with an undisclosed European pharmaceutical company, signing a series of manufacturing deals worth over $668 million. The company will provide manufacturing services through December 2031.
“We are delighted to expand our partnership with the European pharmaceutical company toward our shared commitment to delivering high-quality biopharmaceuticals to patients,” said John Rim, President and CEO of Samsung Biologics, in a press statement.
“As we further expand strategic collaboration with clients worldwide, we also make continued investments in our capabilities and manufacturing technologies. Our goal is to provide the highest-quality services at every stage and deepen our trusted partnerships.”
This latest announcement follows a series of deals that the South Korea-based Samsung Biologics has made across the U.S., Asia, and Europe in the last year, bringing the company’s overall contract value to over $4 billion.
Another notable deal, for example, was in October 2024, when Samsung Biologics signed a whopping $1.24 billion manufacturing agreement with an Asia-based pharmaceutical company.
The company is planning to add antibody-drug conjugate (ADC) services to its portfolio by the end of 2024, with a dedicated manufacturing facility expected to open soon. In February 2024, Samsung Biologics signed a partnership agreement with the South Korean biotech company LegoChem Biosciences to advance the manufacturing of LegoChem’s ADC candidate against solid tumors.
Samsung Biologics is working towards the opening of Plant 5, the first new facility of the company’s second Bio Campus, in April 2025. Located on an area of 96,000m2, Plant 5 holds a capacity of 180,000 liters. Bio Campus II will be fully operational next year, housing additional large-scale manufacturing plants and an open innovation center. The project, which started with the purchase of 360,000m2 of land in July 2022, is worth almost $5.4 billion.
“Given the continuing increase in the demand for outsourced manufacturing of biopharmaceuticals, we are proactively making this investment in alignment with our growth strategy to further strengthen our standing as a leading CDMO,” said Rim at the time in a press release. “The new facility will enable us to provide our customers with even greater innovation and services that will increase speed to market and flexibility.”
